TriangleDISEASE & TREATMENT SETTING
Rectal Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Rectal Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- unresolved
- derivation note
- Derived from NCI topic(s): Rectal Cancer. Strongest NCIt resolution: ambiguous. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
8 more-specific settings
Study evidence for this setting
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
Ipilimumab and Local Radiation for Selected Solid Tumors
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy
S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer
Engagement of Patients With Advanced Cancer
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Project HERO: Health Empowerment & Recovery Outcomes
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients
Indication-specific source history
1996-06-14 · Camptosar (irinotecan hcl trihydrote) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-rectal-cancer
- event id
- fda-6860d88588087217
- event date
- 1996-06-14
- event kind
- accelerated-approval
- drug or regimen
- Camptosar (irinotecan hcl trihydrote)
- source indication text
- Metastatic colon or rectal carcinoma that progressed following 5-FU therapy
- match phrase
- rectal carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b8b10cc9fc766ffd301b
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
1998-10-22 · Camptosar (irinotecan hcl trihydrote) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-rectal-cancer
- event id
- fda-0f7da73a7e39c5ff
- event date
- 1998-10-22
- event kind
- traditional-approval
- drug or regimen
- Camptosar (irinotecan hcl trihydrote)
- source indication text
- Metastatic colon or rectal carcinoma that progressed following 5-FU therapy
- match phrase
- rectal carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b8b10cc9fc766ffd301b
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2002-08-09 · Eloxatin (oxaliplatin) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-rectal-cancer
- event id
- fda-9baa71a66702ad23
- event date
- 2002-08-09
- event kind
- accelerated-approval
- drug or regimen
- Eloxatin (oxaliplatin)
- source indication text
- In combination with infusional 5-FU/LV for metastatic color or rectal carcinoma that progressed during or within 6 months of completion of first-line therapy with bolus 5 -FU/LV and irinotectan
- match phrase
- rectal carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-595e13a3cedd3b1e4109
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2004-01-09 · Eloxatin (oxaliplatin) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-rectal-cancer
- event id
- fda-57de062919b7610c
- event date
- 2004-01-09
- event kind
- traditional-approval
- drug or regimen
- Eloxatin (oxaliplatin)
- source indication text
- In combination with infusional 5-FU/LV for metastatic color or rectal carcinoma that progressed during or within 6 months of completion of first-line therapy with bolus 5 -FU/LV and irinotectan
- match phrase
- rectal carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-595e13a3cedd3b1e4109
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-rectal-cancer
- binding id
- ncit-C118823
- source collection
- ncit-concept
- source key
- C118823
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-rectal-cancer
- binding id
- ncit-C7418
- source collection
- ncit-concept
- source key
- C7418
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-rectal-cancer
- binding id
- ncit-C9382
- source collection
- ncit-concept
- source key
- C9382
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice